[go: up one dir, main page]

WO2017077551A3 - An amorphous nintedanib esylate and solid dispersion thereof - Google Patents

An amorphous nintedanib esylate and solid dispersion thereof Download PDF

Info

Publication number
WO2017077551A3
WO2017077551A3 PCT/IN2016/050378 IN2016050378W WO2017077551A3 WO 2017077551 A3 WO2017077551 A3 WO 2017077551A3 IN 2016050378 W IN2016050378 W IN 2016050378W WO 2017077551 A3 WO2017077551 A3 WO 2017077551A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous
nintedanib
solid dispersion
nintedanib esylate
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2016/050378
Other languages
French (fr)
Other versions
WO2017077551A2 (en
Inventor
Ramakoteswara Rao Jetti
Anjaneyaraju Indukuri
Aggi Ramireddy Bommareddy
Amith SINGH
Soumyajit GHOSH
Rajesh Joshi
Dattatraya Shinde
Mahesh Hublikar
Shivaji BHOITE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of WO2017077551A2 publication Critical patent/WO2017077551A2/en
Publication of WO2017077551A3 publication Critical patent/WO2017077551A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nintedanib base polymorphic forms and processes for preparing the same. A process for the purification of nintedanib base is disclosed. An amorphous form of nintedanib and process for the preparation of the same are also disclosed. A solid dispersion of amorphous nintedanib with pharmaceutically acceptable excipients and processes for the preparation of the same are also disclosed.
PCT/IN2016/050378 2015-11-03 2016-11-02 An amorphous nintedanib esylate and solid dispersion thereof Ceased WO2017077551A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5942/CHE/2015 2015-11-03
IN5942CH2015 2015-11-03

Publications (2)

Publication Number Publication Date
WO2017077551A2 WO2017077551A2 (en) 2017-05-11
WO2017077551A3 true WO2017077551A3 (en) 2017-06-15

Family

ID=57838443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/050378 Ceased WO2017077551A2 (en) 2015-11-03 2016-11-02 An amorphous nintedanib esylate and solid dispersion thereof

Country Status (1)

Country Link
WO (1) WO2017077551A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072849A (en) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-idene Crystal form of methyl]-6-methoxycarbonyl-2-indolinone
JP2024016309A (en) * 2020-12-21 2024-02-07 トーアエイヨー株式会社 solid dispersion
CN116947732A (en) * 2023-07-28 2023-10-27 江苏阿尔法药业股份有限公司 Synthesis method of Nidaminib intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013099A1 (en) * 2002-07-24 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
WO2009071523A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Process for the manufacture of an indolinone derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
PE20091445A1 (en) 2007-12-03 2009-10-19 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013099A1 (en) * 2002-07-24 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
WO2009071523A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Process for the manufacture of an indolinone derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "New crystalline forms of methyl-(3Z)-3-[({4-[N-methyl-2-(4-methyl-1-piperazinyl)acetamido]phenyl}-amino)(phenyl)methylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate (IPCOM000210964D)", IP.COM JOURNAL, 19 September 2011 (2011-09-19), XP002767764 *
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, vol. 198, 1 January 1998 (1998-01-01), SPRINGER, BERLIN, DE, pages 163 - 208, XP008166276, ISSN: 0340-1022 *

Also Published As

Publication number Publication date
WO2017077551A2 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2015166379A3 (en) Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
WO2015145415A3 (en) Ibrutinib solid forms and production process therefor
EP3682982A4 (en) Manufacturing process for large annular forged piece
WO2016038542A3 (en) Solid forms of sofosbuvir
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
WO2018029711A3 (en) Process for the preparation of venetoclax
WO2015159275A3 (en) An improved process for the preparation of rifamycin derivatives
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
EP3728241A4 (en) Process for the preparation of opicapone and intermediates thereof
EP3297678A4 (en) An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
WO2016125190A3 (en) Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
HUE053455T2 (en) Process for the preparation of pyrrolo [3,2-D] pyrimidine compound and its intermediates
EP3265109A4 (en) Processes for preparing pharmaceutically relevant peptides
IL270177B (en) Process for the preparation of deuterated ethanol from d2
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
WO2016024286A3 (en) An improved process for synthesis of lenalidomide
WO2017077551A3 (en) An amorphous nintedanib esylate and solid dispersion thereof
WO2015111076A3 (en) Improved processes for the preparation of highly pure rivaroxaban crystal modification i
WO2015104718A3 (en) A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
WO2014016660A3 (en) Process for preparation of darunavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16828788

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16828788

Country of ref document: EP

Kind code of ref document: A2